Cell Medica Announces Start of Commercial Cell Therapy Manufacture
News Feb 20, 2015
Imperial Innovations Group plc has noted that its portfolio company Cell Medica has announced the start of commercial cell therapy manufacturing at its facility at the Max-Delbrück-Center of Molecular Medicine in Berlin-Buch (Germany). The first product has been successfully manufactured and delivered for use in the patient.
Manufacturing at this site will initially be focused on Cytovir™ CMV for the treatment of patients with cytomegalovirus (CMV) infections following a hematopoietic stem cell (bone marrow) transplant.
Cytovir™ CMV is an individualized immune cell therapy that is comprised of naturally-occurring donor cytotoxic T cells which are transferred from a donor into an immunosuppressed patient, in order to reconstitute their immunity to Cytomegalovirus (CMV). The product is currently available to treat patients in the UK, Ireland and Germany.
Maina Bhaman, Director of Healthcare Investments at Innovations, said: “The Cytovir™ CMV cell therapy is individually manufactured for each patient so the start of commercial manufacture at this facility is a significant landmark in Cell Medica’s development. The facility has been designed specifically to provide high-volume, cost efficient production of GMP-compliant patient-specific cell therapies for distribution across Europe.
“Cell Medica is one of the very first companies of its type to have taken a product from early development into commercial sales with an industrial-scale manufacturing system, which underlines Cell Medica’s position as one of the leaders in this new field of cell therapy.
“Cell Medica will now be able to leverage this manufacturing capability across a broad range of T-cell immunotherapy products, including both infectious disease and its exciting oncology programme.”
On 25 November, Innovations led a £50m series B funding round in Cell Medica alongside co-investors Invesco Asset Management and Woodford Investment Management. Innovations committed £15m to the round and holds a 27.9% stake in the issued share capital of the Company.
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Comments | 0 ADD COMMENT
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018